via pharmamyths.net
Donald Light is a professor of comparative health policy who is concerned that current incentives, laws, and regulations encourage companies to develop many new drugs with few advantages, rather than focusing on really superior new drugs. In the long run, this does not serve the major companies well, because they become less innovative and focus on marketing and government protections of high prices. Small biotechs really try to discover breakthrough drugs, but the major companies are too protected and subsidized for their own good. Adam Smith would not approve.
No comments:
Post a Comment